Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study)

References

1. 1.↵
   Gadavist product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf. Accessed April 11, 2014.
2. 2.↵
   ProHance product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020131s024lbl.pdf. Accessed April 11, 2014.
3. 3.↵
   2. Hao D,
   3. Ai T,
   4. Goerner F, et al

   . MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36:1060–71

   CrossRefPubMed
4. 4.↵
   2. Rohrer M,
   3. Bauer H,
   4. Mintorovitch J, et al

   . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Pintaske J,
   3. Martirosian P,
   4. Graf H, et al

   . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21

   CrossRefPubMed
6. 6.↵
   2. Koenig M,
   3. Schulte-Altedorneburg G,
   4. Piontek M, et al

   . Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol 2013;23:3287–95

   CrossRefPubMed
7. 7.↵
   1. Levine AJ,
   2. Schmidek HH

   2. Lopes MB,
   3. VandenBerg SR,
   4. Scheithauer BW

   . The World Health Organization classification of nervous system tumors in experimental neuro-oncology. In: Levine AJ, Schmidek HH, eds. Molecular Genetics of Nervous System Tumors. New York: Wiley-Liss; 1993:1–36
8. 8.↵
   2. Kleihues P,
   3. Burger PC,
   4. Scheithauer BW

   . The new WHO classification of brain tumours. Brain Pathol 1993;3:255–68

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Katakami N,
   3. Inaba Y,
   4. Sugata S, et al

   . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0M compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411–18

   CrossRefPubMed
10. 10.↵
    Peripheral and Central Nervous System Drugs Advisory Committee. FDA Advisory Committee Briefing Document. New Drug Application 201–277. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240354.pdf. Accessed May 8, 2014.
11. 11.↵
    Center for Drug Evaluation and Research. Statistical Review and Evaluation. Gadovist. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM255169.pdf. Accessed May 8, 2014.
12. 12.↵
    2. Heiland S,
    3. Erb G,
    4. Ziegler S,
    5. Krix M

    . Where contrast agent concentration really matters: a comparison of CT and MRI. Invest Radiol 2010;45:529–37

    CrossRefPubMed
13. 13.↵
    2. Kanal E,
    3. Maravilla K,
    4. Rowley HA

    . Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014;35:2215–26

    Abstract/FREE Full Text
14. 14.↵
    2. Greco A,
    3. Parker JR,
    4. Ratcliffe CG, et al

    . Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001;45:457–63

    CrossRefPubMed
15. 15.↵
    2. Anzalone N,
    3. Scarabino T,
    4. Venturi C, et al

    . Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1mmolGd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139–45

    CrossRefPubMed
16. 16.↵
    2. Seidl Z,
    3. Vymazal J,
    4. Mechl M, et al

    . Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012;33:1050–58

    Abstract/FREE Full Text